A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients with Alcoholic Hepatitis.

//A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients with Alcoholic Hepatitis.

A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients with Alcoholic Hepatitis.

P.I.: Joseph Alcorn, MD

Synopsis– Studying new treatments for alcoholic hepatitis (AH) and investigating the pathophysiology (functional changes) of alcoholic hepatitis (liver inflammation caused by drinking alcohol). The primary purpose of this study is to determine whether treatment with pegfilgrastim (Neulasta®) in addition to prednisolone or pentoxifylline is more effective than treatment with prednisolone or pentoxifylline alone 06 in patients with AH.

2017-10-23T19:10:36+00:00October 23rd, 2017|Categories: Clinical Trials|